Our ImmTAX platform
Immunocore’s ImmTAX™ (Immune Mobilising Monoclonal TCRs Against X Disease) platform is a novel approach to immunotherapy, designed to harness the power of the immune system to potentially fight a range of diseases by taking advantage of the T cell receptor’s ability to target proteins coming from inside an unhealthy cell or a healthy cell under attack.
ImmTAX molecules are bispecifics, with a TCR on one end and an effector function on the other. Unlike most other forms of immunotherapy, our technology can identify intracellular proteins, opening up approximately 90% of disease targets.
As ImmTAX technology is modular, the targeting and effector arms can be switched out depending on the disease target and the intended immune system response.
T cell receptor therapy overview
T cell receptor (TCR) therapy is a new approach to potentially treat disease – including cancer, infectious diseases and autoimmune diseases – by using the immune system to make infected or tumour cells visible and then destroy them, or by turning off the immune system to reduce an autoimmune response.
In contrast to many existing forms of immunotherapy (such as antibodies) – which are limited to extracellular proteins – TCR therapy harnesses intracellular proteins presented as peptides on the cell surface, accounting for approximately 90% of infected or tumour cells.
TCR therapy in cancer
Some cancers can avoid the immune system by displaying antigens in very low levels, making them harder to identify. By affinity-enhancing human TCRs and strapping them to an effector arm that recruits T cells, we can overcome the limitations of our natural immune system and current therapeutic approaches.
In cancer, our TCR therapies (known as ImmTAC™ molecules) are designed to recognise and bind to the chosen target antigen presented by the cell (through an HLA complex). Then the recruiting arm of our bispecific molecules – an anti-CD3 effector function – activates the patient’s own T cells to kill the cancer cell through lytic processes.
We are investigating TCR therapies in several cancers, including ovarian and non-small cell lung cancer, as well as multiple forms of melanoma.
TCR therapy in infectious diseases and autoimmune diseases
TCR technology has the potential to treat other types of disease outside of cancer, particularly infectious diseases and autoimmune diseases.
TCR therapies are being investigated in the treatment of chronic infections by redirecting non-exhausted immune cells to attack infected cells. A primary area of investigation for our ImmTAV™ molecules is a potential functional cure for HIV.
As well as telling the immune system to kill an unhealthy cell, TCRs can also switch off the immune system when it attacks healthy tissue. ImmTAAI™ molecules do this by targeting a specific organ under attack and inhibiting the immune pathway to the rogue T cells.
What are HLA proteins?
Human Leukocyte Antigen (HLA) proteins are crucial for the immune system to distinguish between self and non-self by displaying antigens on the cell surface for T cells to recognise.
In cancer, HLA proteins present abnormal antigens from cancerous cells, enabling T cell receptors on the surface of T cells to recognise tumour cells and eliminate them. However, the immune system (including native T cells) can fail to identify cancer cells on their own at times.
Immunocore’s bispecific T cell receptor (TCR) based technology, ImmTAC™ (Immune Mobilising Monoclonal TCRs Against Cancer), is designed to recognise HLA-presented antigens and redirect the immune response to destroy cancer cells.
There are many different types of HLA proteins, which vary between individuals. A simple blood test can be performed to understand a patient’s HLA status.
Immunocore-sponsored trials
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Learn moreIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)
Learn moreA Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination with Standard of Care Agents in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants with Selected Advanced PIWIL1-Positive Cancers
An open-label dose-escalation study evaluating the safety, pharmacokinetics and antiviral activity of IMC-M113V in HLA-A*02:01 positive subjects with chronic HIV infection who are virologically suppressed
Learn moreExternally-sponsored trials
Check back soon.
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by the UK regulatory agency.
Collaborating on our clinical trials
By taking part in clinical trials, you and your patients can make an important contribution to ongoing research and better understanding of a disease.
Immunocore is committed to supporting third-party research that promote the advancement of medical and scientific knowledge regarding Immunocore’s products and therapeutic areas of interest.
The studies to which we extend support are those that are based on scientifically sound proposals to advance science, clinical medicine, and patient care.
If you have a proposal for externally sponsored research, including investigator sponsored studies or pre-clinical/non-clinical research, you can submit it via our portal.
Externally-sponsored research portalGrants and funding
We recognise that Medical science evolves rapidly with new information becoming available constantly. As part of the healthcare system, we also understand the need to support healthcare professionals in their pursuit of research activities and the most current education to provide the best patient care possible.
There is further need to support patients, caregivers and communities to ensure that they have the information and medicines or treatments to support healthy, quality, and productive lives.
As such, we are proud to have the opportunity to consider funding applications for a number of different activities supporting research and scientific education.
Please visit our Grants & Funding portal for more information about the applications we accept or select from one of the options below.
Externally-sponsored research
Externally sponsored research (ESR) is a study that is proposed and managed by an appropriately qualified external party to Immunocore.
Grants and donations
Coming soon!
Sponsorships
Coming soon!
Request medical information
If you would like further information about our approved or investigational therapies, or our clinical trials, please use the below form to submit a request for information to our Medical and Clinical teams.
Please note: for general non-medical inquiries, please contact us.
CM-GB-KIM-2400006
DOP: July 2025
To visit this site, please confirm you are a healthcare professional:
I am a healthcare professional based in the United Kingdom.
I am a healthcare professional based in the United States.
I am not a healthcare professional based in the United Kingdom or United States.